Vaxcyte Analyst Price Targets - Benzinga

SPY752.88+0.10%QQQ682.55+0.21%BTC/USD76,737.89+0.08%DIA519.00−0.07%GLD362.74+0.30%TLT81.61−0.15%

Premium Services

Premium Services

Vaxcyte Inc

PCVXNASDAQ

Trade with Public

Trade with Public

$60.62

-1.41-2.27%

Last update: Nov 2, 4:29 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Vaxcyte Analyst Price Targets - Benzinga

Vaxcyte Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vaxcyte (PCVX).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

8Buy

1Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$122Upside to Avg. PT+101.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$120
Oct 5, 2026	BTIG	Thomas Shrader	Maintained	Buy	$89
Oct 5, 2026	Needham	Joseph Stringer	PT Raise	Buy	$110→$122
Oct 5, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$116→$125
Sep 28, 2026	B of A Securities	Jason Gerberry	PT Cut	Buy	$133→$130
Sep 25, 2026	Needham	Joseph Stringer	Maintained	Buy	$110
Feb 26, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$85→$89
Feb 2, 2026	Guggenheim	Seamus Fernandez	Maintained	Buy	$116
Jan 7, 2026	Needham	Joseph Stringer	PT Raise	Buy	$90→$110
Nov 10, 2025	BTIG	Thomas Shrader	Maintained	Buy	$85
Oct 16, 2025	BTIG	Thomas Shrader	PT Cut	Buy	$160→$85
Sep 12, 2025	Goldman Sachs	Asad Haider	Initiate	Neutral	$38
Apr 22, 2025	Cantor Fitzgerald	Carter Gould	Initiate	Overweight	—
Apr 8, 2025	Needham	Joseph Stringer	Maintained	Buy	$90
Apr 1, 2025	Goldman Sachs	Chris Shibutani	PT Cut	Buy	$138→$100
Apr 1, 2025	B of A Securities	Jason Gerberry	PT Cut	Buy	$157→$137
Apr 1, 2025	Needham	Joseph Stringer	PT Cut	Buy	$140→$90
Mar 12, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	$160
Feb 26, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	$160
Feb 26, 2025	Needham	Joseph Stringer	Maintained	Buy	$140

Analyst Ratings News

PRO
Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Vaxcyte, Maintains $89 Price Target

BTIG analyst Thomas Shrader reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $89 price target.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Vaxcyte, Raises Price Target to $122

Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $110 to $122.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125

Guggenheim analyst Seamus Fernandez maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $116 to $125.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130

B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $133 to $130.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Vaxcyte, Maintains $110 Price Target

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $110 price target.

Benzinga Newsdesk